December 2014 Br J Cardiol 2014;21(suppl 2):S1–S7
Mr Sotiris Antoniou, Dr Chris Arden, Dr Jan Beyer-Westendorf, Dr David Hargroves, Dr Terry McCormack, Professor Gordon McInnes, Dr Raj Patel, Oliver Segal
When the NOACs (novel oral anticoagulants) were introduced over three years ago, they promised to revitalise the management of conditions such as atrial fibrillation (AF), venous thromboembolism (VTE) and thromboprophylaxis after major joint replacement surgery. Rivaroxaban is currently available in multiple indications, including (but not limited to): prevention of stroke and systemic embolism in adult patients with non-valvular AF, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults. For decades anticoagulant therapy in these conditions had relied on the vitamin K antagon
August 2012 Br J Cardiol 2012;19:107–10
BJCardio Staff
Estimates suggest there will be more than 46,000 cases of acute DVT in England and Wales during 2012, which will rise to nearly 50,000 cases by 2016, due in part to the ageing population. Professor Carole Longson, NICE Health Technology Evaluation Centre Director, said: “For many people, using warfarin is difficult because of the need for regular monitoring with blood tests, dosing adjustments, and the need to be careful about their diet because of warfarin’s interaction with certain foods. Because rivaroxaban does not require frequent blood tests to monitor treatment it represents a potential benefit for many people who have had a DVT, p
March 2012 Br J Cardiol 2012;19:12–3
BJCardio Staff
NICE updates A new ‘Evidence Update’ has been produced by the National Institute for Health and Clinical Excellence (NICE), which summarises selected new evidence relevant to the NICE guideline on the management of chronic heart failure (CHF) in adults in primary and secondary care (clinical guideline 108).NICE says “Whilst Evidence Updates do not replace current accredited guidance, they do highlight new evidence that might generate a future changes in practice.” It says it will welcome feedback from societies and individuals in developing this service. The update is available from www.evidence.nhs.uk/evidence-update-2. New guides
June 2011 Br J Cardiol 2011;18:124–9
Faisal Rahman, Clare J Wotton, Michael J Goldacre
Introduction Varicose veins (VV) are dilated, tortuous, superficial veins found typically in the lower limbs. Haemorrhoids are abnormal distensions of the arteriovenous plexus in enlarged vascular anal cushions, although they are often referred to as varicosities.1 It is unknown whether these two conditions, both classified as disorders of the venous circulatory system,2 are associated with altered risks of other circulatory disorders. If they are, this may suggest clues about shared aetiological mechanisms between VV, haemorrhoids and other circulatory diseases. It would also provide information of prognostic clinical relevance about patien
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits